DOCSLIB.ORG

2019 Preventive Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019 Preventive Drug List 2019 PREVENTIVE DRUG LIST As of July 1, 2019 Preventive medications are used to prevent conditions like high blood pressure, high cholesterol, diabetes, asthma, osteoporosis, heart attack, stroke and prenatal nutrient deficiency. This document shows the most commonly prescribed Some plans have specific coverage requirements for preventive generic and brand name medications preventive medications. For example, some plans may: covered as of July 1, 2019.1 The Preventive Drug List › Require you to pay a copay, coinsurance (the is updated often so it’s important to know that this percentage you pay after you meet your deductible) is not a complete list of the medications your plan and/or deductible (the amount you pay before your covers. Also, your specific plan may not cover all plan starts to pay) to receive coverage for a of the medications on this list. preventive generic medication. Here’s some helpful information about this drug list: › Cover preventive generic medications at 100%, or no › Medications are listed alphabetically by the condition cost ($0) to you. they prevent. You should log into the myCigna® app or website, or › Brand name medications are capitalized and generic check your plan materials, to learn more about how medications are lowercase. your plan covers preventive medications. You can also › Some brand name preventive medications have a click on “Price A Medication” to see how much your generic equivalent. For these medications, the generic medication will cost you at the different pharmacies in will be listed in parenthesis next to the brand name. your network. You can also see if there are lower-cost alternatives available.2 › Some preventive medications are also considered “specialty” medications. Some plans may cover Go generic and save specialty medications on a specialty tier, may limit Your plan covers many preventive medications. coverage to a 30-day supply and/or require you to You should ask your doctor if a lower-cost generic use a preferred specialty pharmacy to receive medication may be right for you. Generics have the coverage. Please log in to the myCigna® app or same strength and active ingredients as brand name website, or check your plan materials, to learn more medications, but often cost much less – in some cases, about how your plan covers specialty medications. up to 85% less.3 Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates. 874996 h All Std/Perf 06/19 Preventive Drug List Asthma related Aldactazide diltiazem 12hr ER Aldactone diltiazem 24hr CD Accolate Altace diltiazem 24hr ER Advair Diskus amiloride diltiazem ER Advair HFA amiloride-HCTZ Dilt-XR albuterol amlodipine Diovan Anoro Ellipta amlodipine-benazepril Diovan HCT Arcapta Neohaler amlodipine-olmesartan Diuril Atrovent HFA amlodipine-valsartan doxazosin Breo Ellipta amlodipine-valsartan-HCTZ Dutoprol Brovana Atacand Dyazide budesonide Atacand HCT Dyrenium caffeine citrate atenolol Edarbi Combivent Respimat atenolol-chlorthalidone Edarbyclor cromolyn Avalide enalapril fluticasone-salmeterol Avapro enalapril-HCTZ Incruse Ellipta Azor Epaned ipratropium benazepril eplerenone ipratropium-albuterol benazepril-HCTZ eprosartan levalbuterol Benicar Exforge levalbuterol concentrate Benicar HCT Exforge HCT levalbuterol HFA Betapace AF felodipine ER Lonhala Magnair betaxolol fosinopril metaproterenol bisoprolol fosinopril-HCTZ montelukast bisoprolol-HCTZ furosemide Perforomist bumetanide guanfacine ProAir HFA Bystolic Hemangeol ProAir RespiClick Byvalson hydralazine Pulmicort Calan hydrochlorothiazide Pulmicort Flexhaler Calan SR Hyzaar QVAR RediHaler candesartan indapamide Serevent Diskus candesartan-HCTZ Inderal LA Singulair captopril Inderal XL Spiriva captopril-HCTZ Innopran XL Spiriva Respimat Cardizem LA Inspra Stiolto Respimat Cardura irbesartan Striverdi Respimat Cardura XL irbesartan-HCTZ Symbicort Carospir isradipine terbutaline Cartia XT Kapspargo Sprinkle Theo-24 carvedilol labetalol Theochron carvedilol ER Lasix theophylline Catapres lisinopril Ventolin HFA Catapres-TTS lisinopril-HCTZ Xolair chlorothiazide Lopressor Xopenex chlorthalidone Lopressor HCT Xopenex Concentrate clonidine losartan zafirlukast Coreg losartan-HCTZ zileuton ER Coreg CR Lotensin Blood pressure related Corgard Lotensin HCT Corzide Lotrel Accupril Cozaar Matzim LA Accuretic Demadex Maxzide acebutolol Demser Maxzide-25 acetazolamide Dibenzyline methazolamide Adalat CC diltiazem methyclothiazide Afeditab CR Brand name medications are capitalized and generic medications are lowercase 2 Blood pressure related Tenormin ezetimibe-simvastatin (continued) terazosin fenofibrate Tiazac fenofibric acid methyldopa tablet timolol Fibricor methyldopa-HCTZ Toprol XL fluvastatin ER metolazone torsemide fluvastatin metoprolol tablet trandolapril gemfibrozil metoprolol ER-HCTZ trandolapril-verapamil ER Lescol metoprolol-HCTZ triamterene-HCTZ Lescol XL Micardis Tribenzor Lipofen Micardis HCT Twynsta Lopid Microzide valsartan Lovaza Minipress valsartan-HCTZ niacin ER minoxidil Vaseretic Niacor moexipril Vasotec Niaspan moexipril-HCTZ Vecamyl omega-3 ethyl esters nadolol verapamil Pravachol nadolol-bendroflumethiazide verapamil ER pravastatin Neptazane verapamil ER PM Prevalite nicardipine verapamil SR Questran nifedipine Verelan Questran Light nifedipine ER Verelan PM rosuvastatin nimodipine Zestoretic simvastatin nisoldipine Zestril Tricor Norvasc Ziac Triglide Nymalize Triklo olmesartan Blood thinner related Trilipix olmesartan-amlodipine-HCTZ Aggrenox Vascepa olmesartan-HCTZ aspirin-dipyridamole ER Vytorin perindopril Brilinta Welchol phenoxybenzamine cilostazol Zetia pindolol clopidogrel Zocor prazosin Coumadin Prestalia dipyridamole Diabetes related Prinivil Durlaza Procardia Please log in to the myCigna app Effient Procardia XL or website, or check your plan Eliquis propranolol materials, to learn more about Jantoven propranolol ER how your plan covers diabetes- Plavix propranolol-HCTZ related preventive medications. Pradaxa Qbrelis prasugrel acarbose quinapril Savaysa Actoplus met quinapril-HCTZ warfarin Actoplus met XR ramipril Xarelto Actos Sorine Zontivity alogliptin sotalol alogliptin-metformin sotalol AF Cholesterol related alogliptin-pioglitazone Sotylize Altoprev Amaryl spironolactone amlodipine-atorvastatin Avandia spironolactone-HCTZ atorvastatin Basaglar Sular Caduet Bydureon Tarka cholestyramine Byetta Taztia XT cholestyramine Light chlorpropamide Tekturna colesevelam Cycloset Tekturna HCT Colestid Duetact telmisartan colestipol Farxiga telmisartan-amlodipine Crestor glimepiride telmisartan-HCTZ ezetimibe Tenoretic Brand name medications are capitalized and generic medications are lowercase 3 Diabetes related metformin ER Osteoporosis related miglitol (continued) Actonel nateglinide glipizide alendronate Onglyza glipizide ER Atelvia Ozempic glipizide XL Binosto pioglitazone glipizide-metformin Boniva pioglitazone-glimepiride Glucophage calcitonin-salmon pioglitazone-metformin Glucophage XR etidronate Prandin Glucotrol Evista Precose Glucotrol XL Forteo QTERN Glucovance Fosamax repaglinide glyburide Fosamax Plus D repaglinide-metformin glyburide micronized ibandronate Riomet glyburide-metformin Miacalcin Soliqua Glynase raloxifene Starlix Glyset risedronate SymlinPen Glyxambi risedronate DR Synjardy Humalog Tymlos Synjardy XR Humulin tolazamide Janumet Prenatal vitamins tolbutamide Janumet XR Toujeo SoloStar Your plan considers all prescription Januvia Tresiba strength prenatal vitamins to be Jardiance Trulicity “preventive.” Kombiglyze XR Victoza Levemir Please check your drug list to Xigduo XR metformin see which tier your plan covers Xultophy prenatal vitamins on. Brand name medications are capitalized and generic medications are lowercase 1. State laws in Texas and Louisiana may require your plan to cover your medications at your current benefit level until your plan renews. This means that if your medication is taken off the drug list, is moved to a higher cost-share tier or needs approval, these changes may not begin until your renewal date. To find out if these state laws apply to your plan, please call Customer Service using the number on the back of your ID card. 2. Prices are not guaranteed, and even though a price is displayed, it’s not a guarantee of coverage. Your costs and coverage may change by the time you fill your prescription at the pharmacy, and medication costs at individual pharmacies can vary. For example, your pharmacy’s retail cash price for a specific medication may be less than the price shown. Coverage and pricing may change. 3. U.S. Food and Drug Administration (FDA) website, “Generic Drug Facts.” Last updated 06/04/18. Cigna reserves the right to make changes to this drug list without notice. Your plan may cover additional medications; please refer to your enrollment materials for details. Cigna does not take responsibility for any medication decisions made by the doctor or pharmacist. Cigna may receive payments from manufacturers of certain preferred brand medications, and in limited instances, certain non-preferred brand medications, that may or may not be shared with your plan depending on its arrangement with Cigna. Depending upon plan design, market conditions, the extent to which manufacturer payments are shared with your plan and other factors as of the date of service, the preferred brand medication may or may not represent the lowest-cost brand medication within its class for you and/or your plan. Health benefit plans vary, but in general to be
Load more

Recommended publications
  • Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability
    European Journal of Pharmaceutics and Biopharmaceutics 163 (2021) 240–251 Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics journal homepage: www.elsevier.com/locate/ejpb Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability D. Dahlgren a, M. Venczel b,c, J.-P. Ridoux b,c, C. Skjold¨ a, A. Müllertz d, R. Holm e, P. Augustijns f, P.M. Hellstrom¨ g, H. Lennernas¨ a,* a Department of Pharmaceutical Biosciences, Biopharmaceutics, Uppsala University, Sweden b Global CMC Development Sanofi, Frankfurt, Germany c Global CMC Development Sanofi, Vitry, France d Physiological Pharmaceutics, University of Copenhagen, Copenhagen, Denmark e Drug Product Development, Janssen R&D, Johnson & Johnson, Beerse, Belgium f Drug Delivery and Disposition, KU Leuven, Leuven, Belgium g Department of Medical Sciences, Gastroenterology/Hepatology, Uppsala University, Sweden ARTICLE INFO ABSTRACT Keywords: Accurate in vivo predictions of intestinal absorption of low solubility drugs require knowing their solubility in Bioavailability physiologically relevant dissolution media. Aspirated human intestinal fluids (HIF) are the gold standard, fol­ Food effects lowed by simulated intestinal HIF in the fasted and fed state (FaSSIF/FeSSIF). However, current HIF charac­ Drug solubility terization data vary, and there is also some controversy regarding the accuracy of FaSSIF and FeSSIF for Human intestinal fluids predicting drug solubility in HIF. This study aimed at characterizing fasted and fed state duodenal HIF from 16 Drug absorption Drug dissolution human volunteers with respect to pH, buffer capacity, osmolarity, surface tension, as well as protein, phos­ Drug delivery pholipid, and bile salt content.
    [Show full text]
  • Pharmacokinetic Interactions of Pioglitazone
    Department of Clinical Pharmacology University of Helsinki Finland PHARMACOKINETIC INTERACTIONS OF PIOGLITAZONE Tiina Jaakkola ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium 2 of Biomedicum, on August 24th, 2007, at 12 noon. Helsinki 2007 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 1 117.7.20077.7.2007 221:11:231:11:23 Supervisors: Professor Pertti Neuvonen, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Docent Janne Backman, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Reviewers: Docent Kimmo Malminiemi, MD, MSc Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland Professor emeritus Pertti Pentikäinen, MD Department of Medicine University of Helsinki Helsinki, Finland Opponent: Professor Kari Kivistö, MD Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland ISBN 978-952-92-2224-7 (paperback) ISBN 978-952-10-4020-7 (PDF, http://ethesis.helsinki.fi ) Helsinki 2007 Yliopistopaino JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 2 117.7.20077.7.2007 221:11:551:11:55 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 3 117.7.20077.7.2007 221:11:551:11:55 CONTENTS CONTENTS ABBREVIATIONS.......................................................................................................................................... 6 LIST OF ORIGINAL PUBLICATIONS.......................................................................................................
    [Show full text]
  • Pharmacokinetic Interactions of Drugs with St John's Wort
    http://www.paper.edu.cn Pharmacokinetic interactions of Journal of Psychopharmacology 18(2) (2004) 262–276 © 2004 British Association drugs with St John’s wort for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi 10.1177/0269881104042632 Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Shen-Quan Pan Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore. Min Huang Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China. Edmund Jon Deoon Lee Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore. Abstract There is a worldwide increasing use of herbs which are often cancer patients receiving irinotecan treatment. St John’s wort did not administered in combination with therapeutic drugs, raising the alter the pharmacokinetics of tolbutamide, but increased the incidence potential for herb–drug interactions. St John’s wort (Hypericum of hypoglycaemia. Several cases have been reported that St John’s wort perforatum) is one of the most commonly used herbal antidepressants. A decreased cyclosporine blood concentration leading to organ rejection. literature search was performed using Medline (via Pubmed), Biological St John’s wort caused breakthrough bleeding and unplanned pregnancies Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their when used concomitantly with oral contraceptives. It also caused inception to September 2003) to identify known drug interaction with serotonin syndrome when coadministered with selective serotonin- St John’s wort. The available data indicate that St John’s wort is a reuptake inhibitors (e.g.
    [Show full text]
  • ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION
    ACCOLATE® (zafirlukast) TABLETS DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o­ tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is: The empirical formula is: C31H33N3O6S Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25­ 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and Reference ID: 3407275 inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness.
    [Show full text]
  • Farmacopea De 2021 (Lista De Medicamentos Cubiertos)
    Planes Medicare Advantage de ConnectiCare Plan ConnectiCare Choice 1 (HMO) Plan ConnectiCare Choice 2 (HMO) Plan ConnectiCare Choice 3 (HMO) Plan ConnectiCare Choice Part B Saver Plan ConnectiCare Flex 1 (HMO-POS) Plan ConnectiCare Flex 2 (HMO-POS) Plan ConnectiCare Flex 3 (HMO-POS) Plan ConnectiCare Passage 1 (HMO) Farmacopea de 2021 (Lista de medicamentos cubiertos) LEA LA SIGUIENTE INFORMACIÓN: ESTE DOCUMENTO CONTIENE INFORMACIÓN SOBRE LOS ME- DICAMENTOS QUE CUBRIMOS EN ESTE PLAN. 00021082, V17 Esta farmacopea se actualizó el 09/01/2021. Para obtener información más reciente o si tiene otras preguntas, comuníquese con Servicios para Miembros de ConnectiCare al 1-800-224-2273, los usuarios de TTY deben llamar al 711, de 8.00 am a 8.00 pm, hora del este, los siete días de la semana, o visite connecticare.com/medicare. Última actualización 09/01/2021 H3528_200567_C Nota para los miembros existentes: Esta farmacopea se ha cambiado desde el año pasado. Revise este documento para asegurarse de que aún se incluyan los medicamentos que usted toma. Cuando esta lista de medicamentos (farmacopea) haga referencia a “nosotros”, “nos” o “nuestro”, significa ConnectiCare. Cuando se refiere a “plan” o “nuestro plan”, significa los planes Medicare Advantage de ConnectiCare. Nuestros planes Medicare Advantage incluyen los planes ConnectiCare Choice 1 (HMO), ConnectiCare Choice 2 (HMO), ConnectiCare Choice 3 (HMO), ConnectiCare Choice Part B Saver, ConnectiCare Flex 1 (HMO-POS), ConnectiCare Flex2 (HMO-POS), ConnectiCare Flex 3 (HMO-POS) y ConnectiCare Passage 1 (HMO). Este documento incluye una lista de los medicamentos (farmacopea) para nuestro plan que se encuentra vigente desde el 09/01/2021 .
    [Show full text]
  • Medicare Part D: 2021 Value Plan Formulary
    | Value Plan | Express Scripts Medicare (PDP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN Formulary ID Number: 21095, Version 10 This formulary was updated on 9/1/2021. For more recent information or other questions, please contact Express Scripts Medicare® (PDP) Customer Service at 1.800.758.4574; New York State residents: 1.800.758.4570 or, for TTY users, 1.800.716.3231, 24 hours a day, 7 days a week, or visit express-scripts.com. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Medco Containment Life Insurance Company and Medco Containment Insurance Company of New York (for members located in New York State only). When it refers to “plan” or “our plan,” it means Express Scripts Medicare. This document includes a list of the drugs (formulary) for our plan, which is current as of September 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year. What is the Express Scripts Medicare Formulary? A formulary is a list of covered drugs selected by Express Scripts Medicare in consultation with a team of healthcare providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]
  • Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS and APPLICATIONS 18048 FM.Qxd 11/11/09 4:31 PM Page Iii
    18048_FM.qxd 11/11/09 4:31 PM Page i Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS AND APPLICATIONS 18048_FM.qxd 11/11/09 4:31 PM Page iii FOURTH EDITION Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications Malcolm Rowland, DSc, PhD Thomas N. Tozer, PharmD, PhD Professor Emeritus Professor Emeritus School of Pharmacy and School of Pharmacy and Pharmaceutical Sciences Pharmaceutical Sciences University of Manchester University of California, San Francisco Manchester, United Kingdom Adjunct Professor of Pharmacology Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego With Online Simulations by Hartmut Derendorf, PhD Distinguished Professor Guenther Hochhaus, PhD Associate Professor Department of Pharmaceutics University of Florida Gainesville, Florida 18048_FM.qxd 11/11/09 4:31 PM Page iv Acquisitions Editor: David B. Troy Product Manager: Matt Hauber Marketing Manager: Allison Powell Designer: Doug Smock Compositor: Maryland Composition Inc./ASI Fourth Edition Copyright © 2011 Lippincott Williams & Wilkins, a Wolters Kluwer business 351 West Camden Street 530 Walnut Street Baltimore, MD 21201 Philadelphia, PA 19106 Printed in China All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government em- ployees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permis- [email protected], or via website at lww.com (products and services).
    [Show full text]
  • Anesthesia/Anti-Convulsants: Carbamazepine Ethosuximide Halothane Lidocaine Phenytoin Valproic Acid Antibiotics: Aminoglycosides
    DRUGS Anesthesia/Anti-Convulsants: Carbamazepine Ethosuximide Halothane Lidocaine Phenytoin Valproic Acid Antibiotics: Aminoglycosides (Generic Examples: Gentamycin; Tobramycin; Amikacin) Amoxicillin Amphotericin B Ampicillin Azithromycin (A Special Macrolide) Ceftriaxone (Prototype 3rd Generation Cephalosporin) Chloramphenicol Chloroquine, Quinine and Mefloquine Ciprofloxacin (Prototype Fluoroquinolone) Clindamycin Demeclocycline (Another Tetracycline) Doxycycline (Prototype Tetracycline) Erythromycin (Prototype Macrolide) Indinavir Isoniazid Ketoconazole Metronidazole Nafcillin (Beta-Lactamase Resistant Penicillin) Praziquantel Rifampin Trimethoprim + Sulfamethoxazole Vancomycin Zidovudine Autonomic Drugs : Atropine Bethanechol Clonidine Cocaine Dobutamine Edrophonium Epinephrine Isoproteronol Labetalol (also Carvedilol) Methylphenidate Metoprolol Phenoxybenzamine Phentolamine Phenylepherine Physostigmine Pilocarpine Pindolol (also Acebutolol) Prazosin Propranolol Reserpine Ritodrine Blood D/O Drugs: Heparin Streptokinase TPA (Tissue Plasminogen Activator) Warfarin Cancer Drugs: 5-Fluoruracil + Folic Acid Bleomycin Busulfan Cisplatin Colchicine Cyclophoshamide Cyclosporine Dacarbazine Doxorubicin = Adriamycin Melphalan Methotrexate Vinchristine Cardiovascular Drugs: Amiodarone Captopril and Enalapril Digoxin Diltiazem Hydralazine Lidocaine Losartan Nifedipine Nitroglycerin and Isosorbide Dinitrate Nitroprusside Procainamide Quinidine Verapamil CNS Drugs: Alprazolam (Another Benzodiazepine) Desipramine (Secondary TCA) Diazepam (Prototype
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics
    Supplementary Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs–Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Table S1. Possible drug-drug interactions of lasmiditan [14,28,31,35–38,40,42,45–47]. The risk or severity of Serum concentration of the Serum concentration of Lasmiditan may serotonin syndrome can following drugs (P-gp lasmiditan (P-gp substrate) increase the be potentially increased and/or BCRP substrates) may potentially increase bradycardic when lasmiditan is may potentially increase when it is combined with effects of the combined with the when combined with the following drugs3,. following drugs. following drugs1,. lasmiditan2,. 5-hydroxytryptophan* afatinib acebutolol alfentanil* alpelisib amlodipine almotriptan* ambrisentan atenolol amitriptiline* apixaban betaxolol amoxapine* belinostat carteolol buspirone* bisoprolol carvedilol citalopram* brentuximab vedotin diltiazem clomipramine* cabazitaxel esmolol cyclobenzaprine* ceritinib felodipine desipramine* cladribine isradipine desvenlavaxine* cobimetinib clobazam ivabradine dexfenfluramine* colchicine* daclatasvir labetalol dextromethorphan* cyclosporine erythromycin levobetaxolol dihydroergotamine* daunorubicin fexofenadine levobunolol dolasetron* delafloxacin lapatinib methyldopa doxepin* digitoxin ritonavir metipranolol doxepin topical* digoxin metoprolol duloxetine* donepezil nadolol eletriptan* doxorubicin nebivolol ergotamine* edoxaban* nicardipine escitalopram*
    [Show full text]
  • Feline Bronchial Asthma: Treatment*
    Article #2 CE An In-Depth Look: FELINE BRONCHIAL ASTHMA Feline Bronchial Asthma: Treatment* Christopher G. Byers, DVM VCA Veterinary Referral Associates, Inc. Gaithersburg,MD Nishi Dhupa, BVM, MRCVS, DACVECC, DACVIM Cornell University ABSTRACT: Treatment of feline bronchial asthma is directed toward promoting bron- chodilation, reducing inflammation, and restoring normal mucus clearance. Therefore, determining and subsequently eliminating the inciting cause(s) of feline bronchial asthma should be the therapeutic priority of veterinary practitioners. Emergency treatment, including supplemental oxygen ther- apy, glucocorticoids, β2-adrenergic agonists, and methylxanthines, is often indicated. Long-term therapy is aimed at further reducing inflam- matory cell infiltration into the tracheobronchial tree and may be accom- plished with inhalant glucocorticoids and antileukotriene medications. eline bronchial asthma is a reversible respiratory condition of the lower airways char- acterized by altered airway immunosensitivity. Many medications, including β2- Fadrenergic agonists and glucocorticoids, are available for treating acute and chronic feline bronchial asthma (see boxes on page 427; Table 1). In addition, novel therapies, most notably adjuvant magnesium and leukotriene modifiers, are currently being *A companion article on intensely investigated as therapeutic adjuncts in managing feline bronchial asthma. pathophysiology and diagnosis appears on page 418. β2-ADRENERGIC AGONISTS β2-adrenergic agonists are used extensively in treating acute
    [Show full text]
  • Cancer Drugs -Oral Blood Thinners (Anticoagulants) (Antineoplastics)
    BLOOD CANCER DRUGS-OTHER (ANTINEOPLASTICS) BLOOD MODIFIERS CANCER DRUGS-OTHER (ANTINEOPLASTICS) anagrelide (P) NEUPOGEN SYLATRON (P) pentoxifylline (M) (P) PROCRIT CANCER DRUGS -ORAL BLOOD THINNERS (ANTICOAGULANTS) (ANTINEOPLASTICS) COUMADIN (M) CANCER DRUGS -ORAL (ANTINEOPLASTICS) enoxaparin (M) anastrozole fondaparinux (P) AFINITOR FRAGMIN (M) bicalutamide PRADAXA (P) (M) BOSULIF warfarin (P) CAPRELSA (M) STROKE PREVENTION exemestane ERIVEDGE (P) (M) GLEEVEC (P) clopidogrel (P) ticlopidine (M) HYCAMTIN INLYTA (P) (M) CANCER DRUGS-OTHER letrozole NEXAVAR (P) (ANTINEOPLASTICS) (P) REVLIMID (P) CANCER DRUGS-OTHER SPRYCEL (ANTINEOPLASTICS) JAKAFI (P) KEY: Preferred Brand-name Drugs (Tier 2) Generic Drugs (Tier 1) P = Prior Authorization Required, Q = Quantity Limit, M = Maintenance Medication CANCER DRUGS -ORAL CENTRAL NERVOUS SYSTEM (ANTINEOPLASTICS) ANTI-PARKINSON DRUGS CANCER DRUGS -ORAL (M) (ANTINEOPLASTICS) pramipexole ropinirole (M) STIVARGA (P) selegiline (M) SUTENT (P) TARCEVA (P) ATTENTION DEFICIT DISORDER (ADD), TASIGNA (P) NARCOLEPSY (P) TEMODAR (M) (P) amphetamine/dextroamphetamine THALOMID (M) (P) dexmethylphenidate TYKERB (M) (P) dextroamphetamine VOTRIENT (M) (P) methamphetamine XALKORI (M) (P) methylphenidate sr XELODA (M) XTANDI (P) methylphenidate ZELBORAF (P) (P) SEIZURE MEDICATIONS (ANTICONVULSANTS) ZOLINZA (P) ZYTIGA carbamazepine extended release (M) carbamazepine (M) CENTRAL NERVOUS SYSTEM clonazepam (M) diazepam (M) ALZHEIMER'S DRUGS divalproex (M) (M) (M) divalproex sodium ARICEPT-23 (M) (M) ethosuximide donepezil
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 06/05/20 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. Approval of non-preferred brand name products may require trial and failure of at least 2 different generic manufacturers. GHS/Change Healthcare Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: Michael Ouellette, RPh PA Requests PA Requests Tel: 802-922-9614 Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Fax: Note: Fax requests are responded to within 24 hrs.
    [Show full text]